<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029584</url>
  </required_header>
  <id_info>
    <org_study_id>18-27008</org_study_id>
    <nct_id>NCT04029584</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Between Rifampin and Fluvastatin</brief_title>
  <official_title>The Effects of Single Dose Rifampin on Pharmacokinetics of Fluvastatin in Uninduced and Hepatically Induced Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of organic anion transporting polypeptide 1B1 (OATP1B1) transporter inhibition at&#xD;
      clinical doses of fluvastatin, a biopharmaceutics drug disposition classification system&#xD;
      (BDDCS) class 1 drug, has not been studied to date. A single dose of IV rifampin can be used&#xD;
      as model OATP1B1 inhibitor to evaluate the significance of OATP1B1 transporter effects on&#xD;
      fluvastatin disposition. A preinduction regimen of oral rifampin followed by a single IV&#xD;
      infusion of rifampin can be used to evaluate the combined effects of enzyme induction and&#xD;
      OATP1B1 transporter inhibition on fluvastatin disposition. A two arm, randomized, open label,&#xD;
      crossover clinical study in healthy, volunteers will be conducted to evaluate the effects of&#xD;
      IV rifampin on fluvastatin disposition in both hepatically induced and uninduced subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effect of rifampin on the pharmacokinetics of fluvastatin will be studied in healthy&#xD;
      volunteers in a two arms, two-period, randomized, unblinded, crossover clinical trial. In the&#xD;
      first arm, subjects will be randomized to one of two treatment groups:&#xD;
&#xD;
      (i)fluvastatin (Lescol®) 20mg capsule (ii) one oral dose of fluvastatin (Lescol®) 20mg&#xD;
      capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal&#xD;
      Saline.&#xD;
&#xD;
      In the second arms, patients will be pretreated with 600mg oral rifampin (two 300mg rifadin&#xD;
      capsule) once daily to induce hepatic enzymes (and transporters) for 5 years. Subjects will&#xD;
      be randomized to one of two treatment groups:&#xD;
&#xD;
      (i) one oral dose of fluvastatin (Lescol®) 20mg capsule (ii) one oral dose of fluvastatin&#xD;
      (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg&#xD;
      in 10ml Normal Saline&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2019</start_date>
  <completion_date type="Actual">April 25, 2020</completion_date>
  <primary_completion_date type="Actual">April 25, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study is a two arm, randomized, open label, crossover, clinical trial. Arm 1 will be conducted in normal healthy volunteers; Arm 2 will be conducted in hepatically induced (by oral rifampin) healthy volunteers.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking will be employed because it is very difficult to mask the effects of rifampin (range discoloration) on subjects.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>AUC will be assessed over a 12 hour study at 0, 0.33, 0.67,1,1.5, 2, 2.5, 3, 4, 6, 9, 12h</time_frame>
    <description>The primary outcome will be fluvastatin Area under the concentration vs time curve (AUC0-12h and AUC0-INF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Cmax will be assessed over a 12 hour study period.</time_frame>
    <description>Secondary outcomes will include fluvastatin maximum plasma concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Tmax will be assessed over a 12 hour study period.</time_frame>
    <description>Secondary outcomes will include time to Cmax (Tmax).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Drug-drug Interaction</condition>
  <arm_group>
    <arm_group_label>Fluvastatin Alone First, Then Fluvastatin +IV Rifampin 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The effect of rifampin on the pharmacokinetics of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.&#xD;
For uninduced periods, subjects will be randomized to receive one oral dose of fluvastatin (Lescol®) 20mg capsule first. Separated by one day of washout, they then receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.&#xD;
Before starting hepatic induced period, subjects will have a washout for greater than one week.&#xD;
To induce hepatic enzyme and transporter, Subjects will be pretreated with 5 days with 600mg oral rifampin. Subjects will be then randomized first to receive a single dose of fluvastatin 20mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluvastatin +IV Rifampin 600 mg First, Then Fluvastatin Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The effect of rifampin on the disposition of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.&#xD;
For uninduced periods, subjects will be randomized to first receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.Separated by one day of washout, subjects will be then receive a single dose of fluvastatin (Lescol®) 20mg capsule.&#xD;
Before starting induction periods, subjects will have a washout greater than one week.&#xD;
To induce hepatic enzyme and transporter, subjects will be pretreated with 5 days with 600mg oral rifampin. subjects will be randomized to receive first one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampin IV</intervention_name>
    <description>A 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline will be used to inhibit hepatic OATP1B1 transporters.</description>
    <arm_group_label>Fluvastatin +IV Rifampin 600 mg First, Then Fluvastatin Alone</arm_group_label>
    <arm_group_label>Fluvastatin Alone First, Then Fluvastatin +IV Rifampin 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifadin 300Mg Capsule</intervention_name>
    <description>Rifadin 600mg by mouth as two 300mg rifadin capsules</description>
    <arm_group_label>Fluvastatin +IV Rifampin 600 mg First, Then Fluvastatin Alone</arm_group_label>
    <arm_group_label>Fluvastatin Alone First, Then Fluvastatin +IV Rifampin 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatin 20 MG</intervention_name>
    <description>one oral dose of fluvastatin (Lescol ) 20mg capsule</description>
    <arm_group_label>Fluvastatin +IV Rifampin 600 mg First, Then Fluvastatin Alone</arm_group_label>
    <arm_group_label>Fluvastatin Alone First, Then Fluvastatin +IV Rifampin 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female, ages 18-65 years old, with no current medical conditions or&#xD;
             active diagnoses as determined by the study doctor based on history, physical exam,&#xD;
             and laboratory evaluations.&#xD;
&#xD;
          2. Subjects who take no other medications two weeks prior to the study and during the&#xD;
             time course of the study including prescription medications, over-the-counter&#xD;
             medications, dietary supplements, or drugs of abuse.&#xD;
&#xD;
          3. Subjects able to maintain adequate birth control during the study independent of&#xD;
             hormonal contraceptives (including hormonal intrauterine devices (IUDs)). Adequate&#xD;
             methods of contraception include use of condoms and copper IUDs.&#xD;
&#xD;
          4. Subjects able to abstain from grapefruit, grapefruit juice, oranges, orange juice,&#xD;
             caffeinated beverages and/or alcoholic beverages from 7am the day before the study to&#xD;
             completion of that study day.&#xD;
&#xD;
          5. Participants determined to have normal liver and kidney function as measured at&#xD;
             baseline ( alanine aminotransferase (ALT): ≤ 2x upper level of normal (ULN), aspartate&#xD;
             aminotransferase (AST): ≤ 2x ULN, serum creatinine (SCr): ≤ 1.5x ULN, T. Bili:&#xD;
             0.1-1.2mg/dL, Albumin: 3.4 - 4.7 mg/dL).&#xD;
&#xD;
          6. BMI between 18.0 - 30 kg/m2 o Subjects capable of fasting from food and beverages at&#xD;
             least 8 hours prior to medication dosing.&#xD;
&#xD;
          7. Be able to read, speak, and understand English.&#xD;
&#xD;
          8. Subjects capable of providing informed consent and completing the requirements of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with active medical problems&#xD;
&#xD;
          2. Subjects on chronic prescription or over the counter (OTC) medication that cannot be&#xD;
             stopped 2 weeks prior to and during the study.&#xD;
&#xD;
          3. Subjects incapable of multiple blood draws (HCT &lt; 30mg/dL)&#xD;
&#xD;
          4. Subjects with a history of rhabdomyolysis&#xD;
&#xD;
          5. Subjects with a history of drug-related myalgias&#xD;
&#xD;
          6. Subjects with a history or diagnosis of hemorrhagic tendencies or blood dyscrasias&#xD;
&#xD;
          7. Subjects with a history of GI bleed or peptic ulcer disease&#xD;
&#xD;
          8. Subjects who smoke tobacco or have ongoing alcohol or illegal drug use&#xD;
&#xD;
          9. Subjects who are pregnant, lactating, or trying to conceive during the study period&#xD;
&#xD;
         10. Subjects allergic to fluvastatin or rifampin or any known component of the medications&#xD;
&#xD;
         11. Anyone who in the opinion of the study investigators is unable to do the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Benet, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <results_first_submitted>April 26, 2021</results_first_submitted>
  <results_first_submitted_qc>August 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 8, 2021</results_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-drug interaction</keyword>
  <keyword>statin</keyword>
  <keyword>rifampin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All study data will be stored and analyzed at University of California San Francisco (UCSF) by the Principal investigator and Key Study personnel. There are no plans of sharing the subjects data with any outside entities.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04029584/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT04029584/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Flyer on campus and Craiglist</recruitment_details>
      <pre_assignment_details>During the uninduced and induced study interventions there were separate randomization procedures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluvastatin Alone First, Then Fluvastatin +IV Rifampin 600 mg</title>
          <description>Subjects received one oral dose of fluvastatin (Lescol®) 20mg capsule.</description>
        </group>
        <group group_id="P2">
          <title>Fluvastatin +IV Rifampin 600 mg First, Then Fluvastatin Alone</title>
          <description>Subjects received one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Uninduced Study 1st Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Uninduced Washout (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Uninduced Study 2nd Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Between (&gt;1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Induced Study 1st Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Induced Washout (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Induced Study 2nd Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy volunteers</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Subjects were randomized to one of two treatment groups: 1) a single oral dose of fluvastatin (Lescol®) 20 mg capsule or 2) a single oral dose of fluvastatin (Lescol®) 20 mg capsule immediately following a 30-min intravenous infusion of rifampin 600 mg in 10 mL normal saline.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.79" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC</title>
        <description>The primary outcome will be fluvastatin Area under the concentration vs time curve (AUC0-12h and AUC0-INF)</description>
        <time_frame>AUC will be assessed over a 12 hour study at 0, 0.33, 0.67,1,1.5, 2, 2.5, 3, 4, 6, 9, 12h</time_frame>
        <population>healthy volunteer</population>
        <group_list>
          <group group_id="O1">
            <title>Fluvastatin Control</title>
            <description>healthy volunteer take a single dose fluvastatin</description>
          </group>
          <group group_id="O2">
            <title>Fluvastatin and IV Rifampin</title>
            <description>Healthy volunteer takes a single IV rifampin prior to oral fluvastatin</description>
          </group>
          <group group_id="O3">
            <title>Fluvastatin + Oral Rifampin Induction</title>
            <description>Healthy volunteers who take oral rifampin for 5 days prior to oral fluvastatin</description>
          </group>
          <group group_id="O4">
            <title>Fluvastatin +Oral Rifampin Induced +IV Rifampin</title>
            <description>Healthy takes five days oral rifampin, and then take one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>AUC</title>
          <description>The primary outcome will be fluvastatin Area under the concentration vs time curve (AUC0-12h and AUC0-INF)</description>
          <population>healthy volunteer</population>
          <units>ng/mL·h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242" spread="83"/>
                    <measurement group_id="O2" value="642" spread="269"/>
                    <measurement group_id="O3" value="124" spread="33.7"/>
                    <measurement group_id="O4" value="371" spread="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-INF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266" spread="86"/>
                    <measurement group_id="O2" value="679" spread="274"/>
                    <measurement group_id="O3" value="136" spread="35.9"/>
                    <measurement group_id="O4" value="385" spread="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Secondary outcomes will include fluvastatin maximum plasma concentration (Cmax).</description>
        <time_frame>Cmax will be assessed over a 12 hour study period.</time_frame>
        <population>healthy volunteers</population>
        <group_list>
          <group group_id="O1">
            <title>Fluvastatin Control</title>
            <description>healthy volunteer take a single dose fluvastatin</description>
          </group>
          <group group_id="O2">
            <title>Fluvastatin and IV Rifampin</title>
            <description>Healthy volunteer takes a single IV rifampin prior to oral fluvastatin</description>
          </group>
          <group group_id="O3">
            <title>Fluvastatin + Oral Rifampin Induction</title>
            <description>Healthy volunteers who take oral rifampin for 5 days prior to oral fluvastatin</description>
          </group>
          <group group_id="O4">
            <title>Fluvastatin +Oral Rifampin Induced +IV Rifampin</title>
            <description>Healthy takes five days oral rifampin, and then take one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Secondary outcomes will include fluvastatin maximum plasma concentration (Cmax).</description>
          <population>healthy volunteers</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176" spread="149"/>
                    <measurement group_id="O2" value="447" spread="342"/>
                    <measurement group_id="O3" value="87.8" spread="37.3"/>
                    <measurement group_id="O4" value="379" spread="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Secondary outcomes will include time to Cmax (Tmax).</description>
        <time_frame>Tmax will be assessed over a 12 hour study period.</time_frame>
        <population>healthy volunteer</population>
        <group_list>
          <group group_id="O1">
            <title>Fluvastatin Control</title>
            <description>healthy volunteer take a single dose fluvastatin</description>
          </group>
          <group group_id="O2">
            <title>Fluvastatin and IV Rifampin</title>
            <description>Healthy volunteer takes a single IV rifampin prior to oral fluvastatin</description>
          </group>
          <group group_id="O3">
            <title>Fluvastatin + Oral Rifampin Induction</title>
            <description>Healthy volunteers who take oral rifampin for 5 days prior to oral fluvastatin</description>
          </group>
          <group group_id="O4">
            <title>Fluvastatin +Oral Rifampin Induced +IV Rifampin</title>
            <description>Healthy takes five days oral rifampin, and then take one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Secondary outcomes will include time to Cmax (Tmax).</description>
          <population>healthy volunteer</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="0.62"/>
                    <measurement group_id="O2" value="1.17" spread="0.72"/>
                    <measurement group_id="O3" value="1.28" spread="0.545"/>
                    <measurement group_id="O4" value="1.23" spread="0.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event was monitored in uninduced arm from study day 1 to day 3. Adverse event was monitored in induced arm from study day -5 to day 3.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Uninduced Healthy Volunteer Fluvastatin Alone</title>
          <description>Subjects randomized to receive one oral dose of fluvastatin (Lescol®) 20mg capsule</description>
        </group>
        <group group_id="E2">
          <title>Uninduced Healthy Volunteer Fluvastatin and Rifampin</title>
          <description>Subjects randomized to receive one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg.</description>
        </group>
        <group group_id="E3">
          <title>Hepatic Induced Healthy Volunteer Fluvastatin Alone</title>
          <description>Subjects pretreated with 5 days with 600mg oral rifampin for enzyme and transporter induction. Subjects randomized to receive one oral dose of fluvastatin 20mg</description>
        </group>
        <group group_id="E4">
          <title>Hepatic Induced Healthy Volunteer Fluvastatin and Rifampin</title>
          <description>Subjects pretreated with 5 days with 600mg oral rifampin for enzyme and transporter induction. Subjects randomized to receive one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Leslie Benet, PhD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 476-3853</phone>
      <email>leslie.benet@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

